{"name":"Medeor Therapeutics, Inc.","slug":"medeor-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MDR-101","genericName":"MDR-101","slug":"mdr-101","indication":"ABCA3-deficient interstitial lung disease","status":"phase_3"}]}],"pipeline":[{"name":"MDR-101","genericName":"MDR-101","slug":"mdr-101","phase":"phase_3","mechanism":"MDR-101 is a gene therapy that delivers a functional copy of the ABCA3 gene to restore surfactant production in patients with ABCA3-deficient interstitial lung disease.","indications":["ABCA3-deficient interstitial lung disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPZ2xOWTFGdGFyaVR6VC1HQkhkSDdoUDRtanJ5X2xQQWFjZHhmVXdSZWo0dVpKQy03TEd3SXY0YUM3eS10aE5FWm1TSExXUnlsY1Z2UkZBb2plOUxJektXdXhWdWQxejBKLW1CNFVFNGFQVGcyZjE3QXpzTmNRdmxDVzAxRi1LeUktMU1teVZSN05RUjBjbUpsREFRMHFXWUtMZ3NVMktxLWE4RTRV?oc=5","date":"2025-07-11","type":"trial","source":"Fierce Biotech","summary":"Relmada terminates license agreement for troubled phase 3 depression asset - Fierce Biotech","headline":"Relmada terminates license agreement for troubled phase 3 depression asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPazhGZ1pSVkxDNFVsYzFpcHhKdlFoM2ZzR0YzMjFhZWtzSVhEOWt0MG9BVnNEQjg0MllnbjFJbGpKNV9KQThkbW9zdzJkVVphT1gxa1hHWlA0NE1PWHNwNkxkRmx3M3NwajB3SXdoVkhVV0ZiWDc0TDA2b0lCSmMwOVdiU0REY1EtMk5zQ1VfY2dnNUk5aUlTYVNySC12R1l1SHZmSy1lOGRyb1JINWNB?oc=5","date":"2025-06-13","type":"pipeline","source":"BioSpace","summary":"Courage Therapeutics Appoints Biopharma Leader Giovanni Ferrara as CEO - BioSpace","headline":"Courage Therapeutics Appoints Biopharma Leader Giovanni Ferrara as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQcnhXckxKdHZXWXVkcmp0Y0thWXV6THdveEpnWVRMV1pkaWNHZVoyTVQwZUhZWk5jRGpIVGt6LV9Od3VkeEVsTV9KSDZueUctSThVZzI1Mm84S1gxd0QwcWFOTFlSd2hST1d5eFFzX19nM1FmbjFxRllGUUZSQkNPbGlR?oc=5","date":"2022-05-25","type":"pipeline","source":"Business Insider","summary":"Exclusive List: Top-Paid Pharma and Biotech CEOs in 2021 - Business Insider","headline":"Exclusive List: Top-Paid Pharma and Biotech CEOs in 2021","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE12Z0NZOWhwNmhWWDBBT25XVnY1V0RkVnRyZkZacVFFdUxsUV8xTlJKWWJrVWsyamRYQkVRcV9QOF94dm01SnNZenJxUjJrdw?oc=5","date":"2020-04-21","type":"pipeline","source":"I95 Business","summary":"Emergent BioSolutions Appoints Karen Smith as CMO - I95 Business","headline":"Emergent BioSolutions Appoints Karen Smith as CMO - I95 Business","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}